WO2001016167A3 - Beta-catenin, tcf-4, and apc interact to prevent cancer - Google Patents

Beta-catenin, tcf-4, and apc interact to prevent cancer Download PDF

Info

Publication number
WO2001016167A3
WO2001016167A3 PCT/US2000/023635 US0023635W WO0116167A3 WO 2001016167 A3 WO2001016167 A3 WO 2001016167A3 US 0023635 W US0023635 W US 0023635W WO 0116167 A3 WO0116167 A3 WO 0116167A3
Authority
WO
WIPO (PCT)
Prior art keywords
catenin
apc
tcf
mini
beta
Prior art date
Application number
PCT/US2000/023635
Other languages
French (fr)
Other versions
WO2001016167A2 (en
Inventor
Nicholas Barker
Johannes C Clevers
Kenneth W Kinzler
Vladimir Korinek
Patrice J Morin
Andrew B Sparks
Bert Vogelstein
Tong-Chuan He
Original Assignee
Univ Johns Hopkins
Nicholas Barker
Johannes C Clevers
Kenneth W Kinzler
Vladimir Korinek
Patrice J Morin
Andrew B Sparks
Bert Vogelstein
He Tong Chuan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins, Nicholas Barker, Johannes C Clevers, Kenneth W Kinzler, Vladimir Korinek, Patrice J Morin, Andrew B Sparks, Bert Vogelstein, He Tong Chuan filed Critical Univ Johns Hopkins
Priority to AU69441/00A priority Critical patent/AU6944100A/en
Publication of WO2001016167A2 publication Critical patent/WO2001016167A2/en
Publication of WO2001016167A3 publication Critical patent/WO2001016167A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A recombinant adenovirus (Ad-Mini-ME) which constitutively expresses the central third of APC includes all of the known β-catenin binding repeats. When expressed in colon cancer cells, Ad-Mini-ME blocked the nuclear translocation of β-catenin and inhibited β-catenin/Tcf-4-mediated transactivation. Accordingly, expression of endogenous targets of the APC/β-catenin/Tcf-4 pathway were down-regulated. Ad-Mini-ME infection of colorectal cancer cell lines with mutant APC but wild-type β-catenin resulted in substantial growth arrest followed by apoptosis. These findings suggest that the β-catenin binding domain in the central third of APC is sufficient for its tumor suppresion activity.
PCT/US2000/023635 1999-09-01 2000-08-29 Beta-catenin, tcf-4, and apc interact to prevent cancer WO2001016167A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU69441/00A AU6944100A (en) 1999-09-01 2000-08-29 Beta-catenin, tcf-4, and apc interact to prevent cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38835499A 1999-09-01 1999-09-01
US09/388,354 1999-09-01

Publications (2)

Publication Number Publication Date
WO2001016167A2 WO2001016167A2 (en) 2001-03-08
WO2001016167A3 true WO2001016167A3 (en) 2001-09-20

Family

ID=23533780

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/023635 WO2001016167A2 (en) 1999-09-01 2000-08-29 Beta-catenin, tcf-4, and apc interact to prevent cancer

Country Status (2)

Country Link
AU (1) AU6944100A (en)
WO (1) WO2001016167A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020061289A1 (en) * 2000-10-04 2002-05-23 Boman Bruce M. Stem cell-based methods for preventing and treating tumor
JP4333955B2 (en) 2002-08-22 2009-09-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 Xenopus cultured cell line expressing mutant APC

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693522A (en) * 1991-11-29 1997-12-02 Chiron Viagene, Inc. Anti-cancer immunotherapeutics
WO1998041631A2 (en) * 1997-03-20 1998-09-24 The Johns Hopkins University β-CATENIN, TCF-4, AND APC INTERACT TO PREVENT CANCER
US5910418A (en) * 1993-03-19 1999-06-08 The Johns Hopkins University Antibodies and assay for detecting mutant APC proteins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693522A (en) * 1991-11-29 1997-12-02 Chiron Viagene, Inc. Anti-cancer immunotherapeutics
US5910418A (en) * 1993-03-19 1999-06-08 The Johns Hopkins University Antibodies and assay for detecting mutant APC proteins
WO1998041631A2 (en) * 1997-03-20 1998-09-24 The Johns Hopkins University β-CATENIN, TCF-4, AND APC INTERACT TO PREVENT CANCER

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
JOHNSON S ET AL: "CASPASE-MEDIATED CLEAVAGE OF APC RESULTS IN AN AMINO-TERMINAL FRAGMENT WITH AN INTACT ARMADILLO REPEAT DOMAIN", FASEB JOURNAL,FED. OF AMERICAN SOC. FOR EXPERIMENTAL BIOLOGY, BETHESDA, MD,US, vol. 13, February 1999 (1999-02-01), pages 339 - 346, XP000917975, ISSN: 0892-6638 *
KAWASOE TERU ET AL: "Isolation and characterization of a novel human gene, DRCTNNB1A, the expression of which is down-regulated by beta-catenin.", CANCER RESEARCH, vol. 60, no. 13, 1 July 2000 (2000-07-01), pages 3354 - 3358, XP000979304, ISSN: 0008-5472 *
MATSUMINE AKIHIKO ET AL: "Binding of APC to the human homolog of the Drosophila discs large tumor suppressor protein.", SCIENCE (WASHINGTON D C), vol. 272, no. 5264, 1996, pages 1020 - 1023, XP000979553, ISSN: 0036-8075 *
MIMORI-KIYOSUE YUKO ET AL: "Adenomatous polyposis coli (APC) protein moves along microtubules and concentrates at their growing ends in epithelial cells.", JOURNAL OF CELL BIOLOGY., vol. 148, no. 3, 7 February 2000 (2000-02-07), pages 505 - 517, XP000979566, ISSN: 0021-9525 *
MORIN P J ET AL: "Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC", SCIENCE,US,AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, vol. 275, 21 March 1997 (1997-03-21), pages 1787 - 1790, XP002088507, ISSN: 0036-8075 *
MORIN PATRICE J ET AL: "Apoptosis and APC in colorectal tumorigenesis.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 93, no. 15, 1996, 1996, pages 7950 - 7954, XP002160047, ISSN: 0027-8424 *
MUNEMITSU SUSAN ET AL: "Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 92, no. 7, 1995, 1995, pages 3046 - 3050, XP002160048, ISSN: 0027-8424 *
RUBINFELD BONNEE ET AL: "Loss of beta-catenin regulation by the APC tumor suppressor protein correlates with loss of structure due to common somatic mutations of the gene.", CANCER RESEARCH, vol. 57, no. 20, 1997, pages 4624 - 4630, XP000979563, ISSN: 0008-5472 *
SHIH IE-MING ET AL: "The beta-catenin binding domain of adenomatous polyposis coli is sufficient for tumor suppression.", CANCER RESEARCH, vol. 60, no. 6, 15 March 2000 (2000-03-15), pages 1671 - 1676, XP000979565, ISSN: 0008-5472 *
SU L -K ET AL: "APC BINDS TO THE NOVEL PROTEIN EB1", CANCER RESEARCH,US,AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, vol. 55, 15 July 1995 (1995-07-15), pages 2972 - 2977, XP002012453, ISSN: 0008-5472 *
SU LI-KUO ET AL: "Association between wild type and mutant APC gene products.", CANCER RESEARCH, vol. 53, no. 12, 1993, pages 2728 - 2731, XP000979561, ISSN: 0008-5472 *
TSIEN R Y: "THE GREEN FLUORESCENT PROTEIN", ANNUAL REVIEW OF BIOCHEMISTRY,PALTO ALTO, CA,US, vol. 67, 1998, pages 509 - 544, XP000946725 *

Also Published As

Publication number Publication date
WO2001016167A2 (en) 2001-03-08
AU6944100A (en) 2001-03-26

Similar Documents

Publication Publication Date Title
WO2000044774A3 (en) Inhibition of stat3 signal transduction for human cancer therapy
Brahimi-Horn et al. Hypoxia signalling controls metabolic demand
Hoque et al. Statin induces apoptosis and cell growth arrest in prostate cancer cells
Packham et al. Ornithine decarboxylase is a mediator of c-Myc-induced apoptosis
Donovan et al. Transforming growth factor-β and breast cancer: cell cycle arrest by transforming growth factor-β and its disruption in cancer
Semenza Regulation of cancer cell metabolism by hypoxia-inducible factor 1
Penta et al. Epigenetics of skin cancer: Interventions by selected bioactive phytochemicals
EP2520652A3 (en) Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associates genes
AU6097094A (en) Antisense polynucleotide inhibition of human growth factor-sensitive cancer cells
AU1586592A (en) Dual chamber rate responsive pacemaker with automatic mode switching
AU6249180A (en) Automatic dual rate i.v. administration
AU3583797A (en) Enhancement of cancer cell death
WO2004058801A3 (en) Modified vaccinia ankara expressing p53 in cancer immunotherapy
Fang et al. Cyclooxygenase-2 in human non-small cell lung cancer
Mishra et al. DNMT1 as a molecular target in a multimodality-resistant phenotype in tumor cells
Khan et al. Epigenetic targets in cancer and aging: dietary and therapeutic interventions
WO2001016167A3 (en) Beta-catenin, tcf-4, and apc interact to prevent cancer
Lee et al. Nrf2-Mediated heme oxygenase-1 upregulation as adaptive survival response to glucose deprivation-induced apoptosis in HepG2 cells
AU2001264769A1 (en) Induction of apoptosis and cell growth inhibition by protein 4.33
Zhang et al. SIRT1 is reduced in gastric adenocarcinoma and acts as a potential tumor suppressor in gastric cancer
Sato et al. Indomethacin inhibits melanogenesis via down-regulation of Mitf mRNA transcription
AU6763098A (en) Methods and compositions for stimulating apoptosis and cell death or for inhibiting cell growth and cell attachment
AU2001256555A1 (en) New inhibotor of apoptosis of nerve cells
Jeon et al. IFNγ-mediated inhibition of cell proliferation through increased PKCδ-induced overexpression of EC-SOD
MY108877A (en) Substituted quinol-2-yl-methoxy-phenylacetic acid derivatives.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP